Dinoprost (Dinoprostum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Uterotonics

Prostaglandins, thromboxanes, leukotrienes and their antagonists

Included in the formulation
  • Enzaprost®-F
    solution c / cavity 
    HINOIN Pharmaceutical and Chemical Products Plant, ZAO     Hungary
    • АТХ:

    G.02.A.D.01   Dinoprost

    Pharmacodynamics:
    Pharmacological action - uterotonizing, stimulating generic activity.
    Refers to prostaglandins - PGF2alpha. Has a pronounced stimulating effect on the myometrium at any time of pregnancy and at any degree of cervical dilatation (due to direct influence on specific functional structures of myometrium cells). Increases the blood levels of acetylcholine, activates adenylate cyclase (accumulates cAMP), stimulates the motility of the gastrointestinal tract.
    Pharmacokinetics:Destroy 15-dehydrogenase prostaglandins in the liver, endothelium of the pulmonary and vessels of other organs. It is excreted mainly by the kidneys (90% in the form of metabolites for 5 hours), about 5% - through the intestine.
    Indications:Intraamnotichesky introduction: interruption of pregnancy (for a period of 16-20 weeks when calculating the first day of the last normal menstruation). Intravenous injection: induction of labor (on time), expulsion of the contents of the uterine cavity in the case of intrauterine fetal death in the III trimester of pregnancy.
    ICD-10

    XV.O00-O08.O04   Medical abortion

    XV.O80-O84.O83.9   Obstetrics allowance for single-childbirth, unspecified

    XVI.P90-P96.P95   Fetal death for unspecified cause

    Contraindications:Hypersensitivity, bronchial asthma (including history), chronic obstructive pulmonary disease, lung disease in the acute stage, ulcerative colitis, Crohn's disease, thyrotoxicosis, glaucoma, acute infections, inflammatory diseases of the pelvic organs (including clinically expressed chorioamnionitis, cervicitis ), rupture of membranes (increased risk of intravascular absorption of dinoprost), a clinically narrow pelvis, a significant disproportion in the size of the pelvis of the mother and fetal head, improper presentation of the fetus, uncontrolled arterial hypertension, sickle-cell anemia, cesarean section or large surgical interventions on the uterus (in the anamnesis), difficult and / or traumatic births in the history, 6 or more full-term pregnancies (in the anamnesis), spotting from the genital tract of unexplained etiology during pregnancy, previous fetal distress.
    Carefully:Dinoprost can be used only in obstetric-gynecological hospitals in the presence of an intensive care unit.
    Pregnancy and lactation:It is used in pregnancy strictly according to indications.The effect of dinoprost on the fetus is not fully understood.
    Dosing and Administration:Intramuscular, intravenously. Dosage regimen is individual, strictly under the supervision of a doctor.
    Side effects:
    From the side of the cardiovascular system and blood (hematopoiesis, hemostasis): increased blood pressure, lability of blood pressure, tachycardia, development or worsening of heart failure, AV-blockade II degree, ventricular arrhythmia, bradycardia; heart failure, DIC syndrome, pulmonary embolism, thrombophlebitis of the pelvic veins, petechiae, nasal bleeding.
    On the part of the respiratory system: shortness of breath, cough, hyperventilation of the lungs, bronchospasm.
    From the nervous system and sensory organs: headache, dizziness, drowsiness, weakness, loss of consciousness, euphoria, paresthesia, diplopia, burning in the eyes, miosis.
    On the part of the digestive system: nausea, vomiting, diarrhea, paralytic intestinal obstruction, hiccough, abdominal pain.
    From the genitourinary system: increased uterine musculature contractility, uterine pain, uterine rupture, urinary incontinence, dysuria, hematuria, atony or bladder hypertension.
    Other: bradycardia in the fetus, low index on the Apgar scale in the newborn; allergic reactions, anaphylactoid reactions, chills, fever, postpartum infections, hypovolemic shock, increased sweating, muscle spasms, polydipsia, pain of varying localization and intensity; with intravenous injection - phlebitis, hyperthermia.
    Overdose:There is no evidence of drug overdose, since the drug is administered exclusively under the supervision of a physician under strict indications.
    Interaction:It is not recommended to apply simultaneously with other drugs that increase the uterine contractility: an excessive increase in the tone of the myometrium, leading to rupture of the uterus or cervix, especially if there is no adequate opening. Furosemide inhibits the metabolism and excretion of kidney metabolites of dinoprost. Progesterone reduces the toxic effect of dinoprost.
    Special instructions:The drug is used only in obstetric-gynecological hospitals in the presence of an intensive care unit under the supervision of an obstetrician-gynecologist.
    Instructions
    Up